URINE BASED MOLECULAR TEST FOR PROSTATE CANCER

Information

  • Research Project
  • 2012615
  • ApplicationId
    2012615
  • Core Project Number
    R43CA074641
  • Full Project Number
    1R43CA074641-01
  • Serial Number
    74641
  • FOA Number
  • Sub Project Id
  • Project Start Date
    6/1/1997 - 27 years ago
  • Project End Date
    11/30/1997 - 27 years ago
  • Program Officer Name
    COUCH, JENNIFER A
  • Budget Start Date
    6/1/1997 - 27 years ago
  • Budget End Date
    11/30/1997 - 27 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/27/1997 - 27 years ago

URINE BASED MOLECULAR TEST FOR PROSTATE CANCER

The long term goals of this project ar to: 1) develop a sensitive and accurate diagnostic urine test for prostate cancer; and, 2) create a "prostate profile" identifying prognostic subgroups of prostate cancer based on expression of molecular markers. We detected in urine sample the expression of specific genetic markers which appear in men with prostate cancer. This Phase I application will determine the feasibility of utilizing this test as a diagnostic and/or prognostic indicator in prostate cancer. We will initially optimize the collection of urine specimens with respect to cellular viability and RNA quality and quantity. Next, we will evaluate at least 100 additional urine specimens for specific gene expressions and, finally evaluate the relationship of laboratory data and clinical data for interpretation and validation of the prostate profile as a diagnostic screening test. PROPOSED COMMERCIAL APPLICATION: There will be 317,000 new cases of prostate carcinoma diagnosed in 1996. While serum PSA has improved screening, more sensitive and specific means are needed to screen and confirm cases of prostate cancer. It is recommended that all men over 50 be screened. A diagnostic urine test which a\was more accurate could improve screening and obviate more costly confirmatory procedures and tests. The commercial application of such a test would be vast.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    NORTHWEST BIOTHERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    Bethesda
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20814
  • Organization District
    UNITED STATES